Research Article

Three Ingredients of Safflower Alleviate Acute Lung Injury and Inhibit NET Release Induced by Lipopolysaccharide

Yun-peng Wang, Yu Guo ⓘ, Ping-shan Wen, Zhen-zhen Zhao, Jian Xie ⓘ, Kai Yang, Qing Yang, Jia-feng Wang ⓘ, and Xiao-ming Deng ⓘ

Faculty of Anesthesiology, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai 200433, China

Correspondence should be addressed to Jia-feng Wang; jfwang@smmu.edu.cn and Xiao-ming Deng; deng_x@yahoo.com

Xuebijing injection is a Chinese herb compound to treat sepsis in China, but it contains many different kinds of components, and each component may have different effects in treating sepsis. The present study was performed to investigate the effect of three ingredients of Xuebijing, safflor yellow A (SYA), hydroxysafflor yellow A (HSYA), and anhydrosafflor yellow B (AHSYB), in lipopolysaccharide- (LPS-) induced acute lung injury (ALI). LPS (10 mg/kg) was injected intratracheally to induce acute lung injury in mice, which were then treated with SYA, HSYA, and AHSYB. The blood, bronchoalveolar lavage fluid (BALF), and lung tissues were collected to detect degree of lung injury, level of inflammation, and neutrophil extracellular traps (NETs). In vitro experiments were performed using HL-60 cells stimulated with phorbol myristate acetate (PMA). Lung injury induced by LPS was alleviated by SYA, HSYA, and AHSYB as demonstrated by the histopathologic test. The three components inhibit LPS-induced elevation of the levels of inflammatory factors and wet-to-dry weight ratio as well as the amount of protein and cells in the BALF. They also induced a remarkably less overlay of myeloperoxidase (MPO) and histone in the immunofluorescence assay and reduced level of MPO-DNA complex in plasma. The in vitro assay showed a similar trend that the three components inhibited PMA-induced NET release in neutrophil-like HL-60 cells. Western blot demonstrated that phosphorylation of c-rapidly accelerated fibrosarcoma (c-Raf), mitogen-activated protein kinase ERK kinase (MEK), and extracellular signal-regulated kinase (ERK) in the lungs of LPS-challenged mice, and PMA-treated HL-60 cells were all significantly reduced by SYA, HSYA, and AHSYB. Therefore, our data demonstrated that three components of XBJ, including SYA, HSYA, and AHSYB, showed a protective effect against LPS-induced lung injury and NET release.

1. Introduction

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection [1]. Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is present in a large proportion of septic patients and may lead to an increased mortality [2]. Neutrophils play an important role in innate immunity. When the host is challenged by the pathogenic microorganisms, neutrophils will be mobilized and migrate to the infectious locus driven by the concentration gradient of chemokines such as interleukin-8 (IL-8), C5a, fMLP, and leukotriene B4 [3]. The neutrophils recruited to the infected sites can kill the pathogens by phagocytosis and then be eliminated by macrophages [4]. On the other hand, it is believed that the activation, infiltration, and delayed elimination of neutrophils have a major effect on the progression of ALI/ARDS [5]. Neutrophil extracellular traps (NETs) are primarily composed of cellular-free DNA, histones, and globular proteins such as myeloperoxidase (MPO) [6]. They work as a valuable antimicrobial defense mechanism; however, accumulating evidences demonstrate that excessive formation of NETs contributes to the pathogenesis of several diseases, such as appendicitis, acute lung injury, systemic lupus erythematosus, and sepsis [7–9]. During these conditions, excessive histones and MPO are toxic to epithelial cells and endothelial cells [9], and NETs may be involved in the pathogenesis of ALI/ARDS as a potential therapeutic target against lung injury.

Xuebijing (XBJ) is a traditional Chinese herbal prescription which is widely used in treating sepsis in China [10]. It has been also reported to have a positive effect on the treatment of ALI/ARDS related to sepsis [11, 12] and community-acquired pneumonia [13]. XBJ contains the following five main Chinese herbs, including safflower, red peony root, Szechuan Lovage Rhizome, Radix Salviae Miltiorrhizae, and Chinese angelica. Among these herbs, safflower is commonly used for improving microcirculation, relieving pain, and inhibiting inflammation in traditional medicine in China, Middle East, and other countries [14]. We speculated that the effects of safflower on microcirculation and inflammation might be useful in relieving sepsis-induced pulmonary inflammation, but we did not know which molecules within safflower provided these effects. Some researchers analyze the main ingredients of XBJ by mass spectrometry and identified several different ingredients from XBJ, among which safflor yellow A (SYA), hydroxysafflor yellow A (HSYA), and anhydrosafflor yellow B (AHSYB) were derived from safflower [15]. Therefore, the present study was performed to investigate the effect of SYA, HSYA, and AHSYB on lipopolysaccharide- (LPS-) induced lung injury in mice.

2. Materials and Methods

2.1. Experimental Animals and Cells. Male C57BL/6J mice that were 6-8 weeks of age and free of specific pathogens were obtained from the Research Animal Center of Navy Medical University (Shanghai, China). All experimental animals used in this study were approved by the Institutional Animal Care and Use Committee of the Navy Medical University. All experiments were performed in accordance with the relevant guidelines and regulations.

The cell line used was the human leukemia cell line, HL-60. The cells were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA) and maintained at 37°C with 5% CO_2. With this line, differentiation to mature granulocytes can be induced by compounds such as dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO, USA).

2.2. In Vivo Experiments. The acute lung injury model was established as described previously [16]. Briefly, the mice were anesthetized with sevoflurane (Hengrui, Lianyungang, Jiangsu, China). After exposing the trachea, a trimmed sterile 31-gauge needle was inserted into the tracheal lumen. LPS (Sigma, St Louis, MO, USA) diluted in endotoxin-free saline was intratracheally (IT) injected at a dose of 10 mg/kg in 50 μl saline.

To treat ALI mice, SYA (ChromaDex, Irvine, CA, USA), HSYA (Santa Cruz, Dallas, TX, USA) and AHSYB (Nature Standard, Shanghai, China) was dissolved in saline and intraperitoneally administered immediately after the injection of LPS. All these three compounds were given at 5×10^{-5} mol/kg in 400 μl saline [17]. The materials required for the experiment were obtained after 24 hours.

2.3. In Vitro Experiments. The HL-60 cells cultured in 10% FBS medium were treated with DMSO (1.25%) to induce the differentiation into neutrophil-like cells [18]. After five days, the cells were stimulated with PMA (MedChemExpress, Monmouth Junction, NJ, USA) (100 ng/ml, dissolved in DMSO) or medium or DMSO. Then, SYA, HSYA, and AHSYB (160 mg/l) were added into the medium [19]. Three hours later, cells were harvested after centrifugation while the supernatant was collected for other use.

2.4. Histology and Immunofluorescence. Lungs were fixed in 4% paraformaldehyde solution for more than 48 hours. Subsequently, the lungs were embedded in paraffin and sectioned. Sections were then stained with hematoxylin and eosin (HE) after deparaffinization. Alveolar congestion, hemorrhage, aggregation of inflammatory cells, and the thickness of the alveolar walls were assessed under a light microscope. The result was semiquantified by two independent pathologists according to the criteria reported previously [20, 21].

For immunofluorescence assay, sections were incubated overnight with various primary antibodies at 4°C after blocking. And secondary antibodies with different fluorescence colors were added to the sections for 1 h at room temperature. After being rinsed and mounted with glycerol, the sections were recorded using fluorescence microscopy.

2.5. Enzyme-Linked Immunosorbent Assays (ELISAs) of Cytokine. Mouse blood was collected from the postocular venous plexus and centrifuged. The plasma was harvested to detect the cytokine level using TNF-α or IL-6 ELISA kits (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. The results were measured using a microtiter plate reader at 450 nm.

2.6. Lung Wet-to-Dry Weight Ratio. The wet weight of the lungs was measured instantly after lung tissues were harvested. Then, the lungs were incubated in an oven at 80°C for 3 days to remove moisture, and the dry weight was measured. The wet-to-dry weight (W/D) ratio was calculated to assess the edema.

2.7. BALF Analysis. The BALF was obtained by intratracheal injection with 1 ml cold PBS. Then, the BALF was centrifuged at 1500 rpm for 10 min. The protein concentration in the supernatant was assessed with a BCA detection kit (Thermo Scientific, Rockford, IL, USA). Briefly, solution A and solution B were mixed and then added into each sample. After incubation in 37°C for 30 min, the OD values at the length of 540 nm were read. Then, the protein concentration of each sample was obtained according to the standard curve.

The cells in the BALF were collected and stained with anti-Ly6G-PE and anti-CD11b-APC (eBiosciences, San Diego, CA, USA) to detect neutrophils by flow cytometry. Flow cytometry data was obtained using a FACSCanto II flow cytometer (BD Bioscience, San Jose, CA, USA) and analyzed by FlowJo software, version 7.6.1 (Tree Star, Ashland, OR, USA).

2.8. Detection of MPO-DNA. To quantify NETs in mouse plasma and in cell culture supernatant, a capture ELISA

based on MPO associated with DNA was applied [22]. For the capture antibody, 5 μg/ml anti-MPO Ab (Invitrogen, Carlsbad, CA, USA) was coated onto 96-well plates (dilution 1 : 500 in 50 μl) overnight at 4°C. After washing 3 times (300 μl each), 20 μl of samples was added to the wells with 80 μl incubation buffer containing a peroxidase-labeled anti-DNA antibody (Cell Death ELISA PLUS, Roche, Indianapolis, IN, USA; dilution 1 : 25). The plate was incubated for 2 hours, shaken at 300 rpm at room temperature. After 3 washes (300 μl each), 100 μl peroxidase substrate (ABTS) was added. Absorbance at 405 nm wavelength was measured after 20 minutes of incubation at room temperature in the dark. Values for soluble NET formation were expressed as fold increase in absorbance above control.

2.9. Western Blot Analysis. The lung tissues or the HL-60 cells were lysed in RIPA Buffer (1 mM EDTA pH 8.0, 50 mM Tris-HCl pH 8.0, 2% SDS, and 5 mM DTT), and their protein concentration was determined by the BCA assay (Beyotime, Shanghai, China). The total protein was separated by a SDS-PAGE gel and transferred to PVDF (polyvinylidene fluoride) membranes (Immobilon, Merck KGaA, Darmstadt, Germany) and then blocked with 5% nonfat dry milk in PBST (phosphate-buffered saline with Tween) with a pH of 7.5. The membranes were incubated with primary antibodies: c-Raf, P-c-Raf, MEK, P-MEK, ERK, and P-ERK (Cell Signal Technology, Beverly, MA, USA, diluted at 1 : 1000) for 4 hours at room temperature or overnight at 4°C. The secondary antibodies, goat anti-mouse IgG-HRP and goat anti-rabbit IgG-HRP (Engibody Biotechnology, Milwaukee, WI, USA, diluted at 1 : 2000), were incubated for 2 hours at room temperature. Finally, the protein bands were detected by an enhanced chemiluminescence kit (Pierce, Rockford, IL, USA). The relative semiquantitative analysis was based on optical density with ImageJ software, version 1.51 (Rawak Software, Inc. Germany).

2.10. Statistical Analysis. Statistical analysis was conducted with GraphPad Prism 7 (GraphPad Software Inc., CA, USA) using one-way analysis of variance (ANOVA) and the 2-tailed Student t-test. All data were presented as mean values ± standard error of mean. P values < 0.05 were considered statistically significant.

3. Results

3.1. SYA, HSYA, and AHSYB Alleviate LPS-Induced Lung Histopathologic Changes. Lung injury was assessed by HE staining of lung tissue 24 hours after LPS injection. As shown in Figure 1(a), in the LPS group, the lung tissue of the mice was severely damaged with the destroyed alveolar structure, edematous and thickened pulmonary septum, and a large number of inflammatory cells infiltrated in the interstitium and alveoli. Although inflammatory reactions were also observed in the lung tissues of the SYA group, HSYA group and AHSYB group, the impairment was significantly lighter, with less inflammatory cells infiltrated and milder lung interstitial damage (Figure 1(a)). The pathological scores indi-

cated that SYA, HSYA, and AHSYB could alleviate the lung injury induced by LPS (Figure 1(b)).

3.2. SYA, HSYA, and AHSYB Suppress LPS-Induced Inflammatory Responses in the Lungs. Inflammatory cytokines play a key role in LPS-induced ALI. We measured the level of TNF-α and IL-6 in plasma and BALF to indicate the severity of inflammatory responses in the lungs. Compared with the control group, LPS significantly increased the secretion of TNF-α and IL-6 both in plasma and BALF, and this trend was reversed by SYA, HSYA, and AHSYB (Figure 2). Thus, we can infer that SYA, HSYA, and AHSYB can suppress LPS-induced lung inflammatory cytokine production.

3.3. SYA, HSYA, and AHSYB Protect the Permeability of the Lungs in LPS-Induced ALI. In ALI, the permeation of macromolecules and fluid into the interstitium was increased when the endothelial cell barrier was damaged. The wet-to-dry weight ratio of the lungs and total protein concentration of BALF are a signal to assess the edema in ALI. 24 hours after LPS injection, the wet-to-dry weight ratio of the lungs was increased, and HSYA and AHSYB blocked the increase while SYA did not show this effect (Figure 3(a)). But SYA, HSYA, and AHSYB all significantly reduced the concentrations of total proteins in BALF after LPS injection (Figure 3(b)). These data implied that SYA, HSYA, and AHSYB relieved the severity of increased lung permeability in ALI caused by LPS.

3.4. SYA, HSYA, and AHSYB Block the Inflammatory Cell Infiltration in the Lungs. In the progression of ALI, neutrophils accumulate in the lungs following the chemokine release from macrophages and mediate lung injury. Thus, the effect of SYA, HSYA, and AHSYB on the infiltration of inflammatory cells in the lungs was investigated. It was observed that LPS increased the number of total cells and neutrophils in BALF 24 hours after LPS injection. However, after the administration of SYA, HSYA, and AHSYB, the number of total cells and neutrophils in BALF was reduced markedly (Figure 4). These data indicated that SYA, HSYA, and AHSYB could inhibit the inflammatory cell infiltration in ALI caused by LPS.

3.5. SYA, HSYA, and AHSYB Inhibit NET Formation in Impaired Lungs. NETs mainly consist of DNA, histone, and MPO; thus, we stained the lung section with these primary antibodies. The LPS group mouse lung section contained more histone and MPO compared with the control group, while SYA, HSYA, and AHSYB reversed this tendency (Figure 5). These results reflect directly that SYA, HSYA, and AHSYB could reduce the production of NETs.

3.6. SYA, HSYA, and AHSYB Decreased NETs In Vivo and In Vitro. Generally, NETs can be detected by ELISA with a capture antibody against MPO-DNA. In vivo, we found that absorbance at 405 nm wavelength was increased in the LPS group compared with the control group. Treatment with SYA, HSYA, and AHSYB eliminated these alterations. The similar results were also observed in PMA-stimulated HL-60 cells in vitro. SYA, HSYA, and AHSYB decreased the

(a)

(b)

Figure 1: Effects of SYA, HSYA, and AHSYB on LPS-induced histopathologic changes in the lungs. (a) 24 hours after LPS injection, the lungs in each group were prepared for histological evaluation. Representative histological section of the lungs was stained by HE staining, magnification (100x, bar = 200 μm; 200x, bar = 100 μm). (b) The lung injury scores were determined. The values presented are mean ± SEM, $^{##}P < 0.01$ vs the control group; $^{#}P < 0.05$ vs the control group; $^{*}P < 0.05$ vs the LPS group; $^{**}P < 0.01$ vs the LPS group.

upregulation of OD_{405} induced by addition of PMA to the medium (Figure 6).

3.7. SYA, HSYA, and AHSYB Inhibit the Raf/MEK/ERK Signaling Pathway. The activation of the Raf/MEK/ERK signaling pathway is necessary for NET formation, and thus, we examined the effect of SYA, HSYA, and AHSYB on phosphorylation level of c-Raf, MEK, and ERK in lung homogenate and in HL-60 cell lysate to provide further evidence of the change in pathways of NET formation. As shown in Figure 7, the levels of the phosphorylated c-Raf, MEK, and ERK were markedly increased after LPS challenge. SYA, HSYA, and AHSYB inhibited the activation of these signaling molecules.

Similar trends of the phosphorylated level of c-Raf, MEK, and ERK were observed in the cell experiment. As shown in Figure 8, SYA, HSYA, and AHSYB inhibit the Raf/MEK/ERK signaling pathway which is essential for NET formation.

4. Discussion

Our present study demonstrated that three main constituents of safflower identified in XBJ, including SYA, HSYA, and

AHSYB, could alleviate pulmonary inflammation and impairment induced by LPS. They can also reduce the formation of NETs and inhibit the Raf/MEK/ERK pathway in lungs challenged by LPS and in neutrophil-like HL-60 cells stimulated by PMA.

SYA, HSYA, and AHSYB are among the main constituents of safflower, which is one of the five main herbs in XBJ. Safflower is a traditional herb in Chinese medicine with antioxidant and anti-inflammatory effects. It has also been reported to protect against ischemic heart disease [23]. Chinese medicine is always composed of several different kinds of herbs, and each herb may have many biological molecules with various therapeutic effects. It is important for us to understand the exact effect of each biological molecule within these herbs for developing monomeric drug. Therefore, the present study was performed to investigate the role of SYA, HSYA, and AHSYB on LPS-induced lung injury and the underlying pathophysiological changes.

It is really interesting to find that the three constituents of safflower can inhibit NET formation. The process of NET release represents a special way of neutrophil cell death called "NETosis" [24]. The main protein components of NETs are histones, followed by granzymes and peptides, including

(a)

(b)

(c)

(d)

FIGURE 2: Effects of SYA, HSYA, and AHSYB on the production of inflammatory cytokines in LPS-induced ALI. (a) TNF-α in plasma 24 h after ALI. (b) IL-6 in plasma 24 h after ALI. (c) TNF-α in BALF 24 h after ALI. (d) IF-6 in BALF 24 h after ALI. The values presented are mean ± SEM, $^{##}P < 0.01$ vs the control group; $^{#}P < 0.05$ vs the control group; $^{*}P < 0.05$ vs the LPS group; $^{**}P < 0.01$ vs the LPS group.

neutrophil elastase (NE), MPO, cathepsin G, leukocyte protease 3 (PR3), lactoferrin, lysozyme C, and calprotectin [25]. In subsequent studies, NETs were found to be associated with a variety of diseases, including infectious [26, 27] and non-infectious diseases [28–30]. NETs protect the host by capturing and killing pathogens; however, excessive NET formation can be harmful [31]. It has been reported that NETs play an important role in intravascular thrombosis, disseminated intravascular coagulation, and multiple organ dysfunction, and these pathological processes can increase the incidence and mortality of sepsis [32, 33]. Thus, NETs are a promising target against ALI/ARDS, and the three constituents of safflower may provide a new insight for drug development.

The three constituents of safflower have been investigated in other animal models. It was confirmed that SYA could protect neonatal rat cardiomyocytes against anoxia/reoxygenation injury in vitro [34]. There have been a large number of studies showing the protective effects of HSYA on the cardiovascular system [35–37], nervous system [38, 39], liver [40, 41], lung [42, 43], and others. It was also found to inhibit certain tumors [44, 45] and has a certain impact on metabolism [46]. But there are currently few studies on the pharmacological effect of AHSYB. Our present study is the first to investigate the three constituents on LPS-induced lung injury simultaneously since they are the main components of XBJ.

XBJ is a Chinese patent medicine that was approved for treating sepsis. Its antiendotoxin and anti-inflammatory effects have been demonstrated in many animal experiments and clinical trials for the treatment of sepsis. A meta-analysis which consists of 16 RCTs suggested that XBJ may improve the 28-day mortality rate, APACHE scores, WBC count, and body temperature of septic patients without serious adverse events [10]. Furthermore, researchers have studied that XBJ can ameliorate ALI induced by sepsis via several different mechanisms. Wang et al. found that XBJ may inhibit

(a)

(b)

Figure 3: Effects of SYA, HSYA, and AHSYB on the edema in LPS-induced ALI. (a) Lung tissues were weighed to calculate the W/D ratio. (b) BCA assay was used to determine the total protein concentration in BALF. The values presented are mean ± SEM, $^{#}P < 0.05$ vs the control group; $^{*}P < 0.05$ vs the LPS group.


(a)

(b)

Figure 4: Effects of SYA, HSYA, and AHSYB on inflammatory cells induced by LPS. (a) The total cells detected by flow cytometry in BALF. (b) The neutrophils detected by flow cytometry in BALF. The values presented are mean ± SEM, $^{##}P < 0.01$ vs the control group; $^{#}P < 0.05$ vs the control group; $^{*}P < 0.05$ vs the LPS group; $^{**}P < 0.01$ vs the LPS group.

the releases of proinflammatory cytokines through the HMGB1/RAGE axis [11]. Another study indicated that XBJ may have an impact on lung capillary leakage by upregulating Tollip expression and inhibiting lung inflammatory responses and oxidant stress and protecting lung permeability [12]. Other mechanisms may include the shift of macrophage from M1 to M2 phenotype [47], inhibition of IL-6 expression, and maintenance of IL-10 expression at the protein and mRNA levels [48]. Our present study may increase our understanding of the effects and mechanisms of XBJ during sepsis and organ injury.

It has been proved that XBJ injection had a significant efficacy in treating sepsis because of its bioactive compo-

nents which can inhibit the NF-κB pathway [49]. SYA and HSYA are two of these bioactive components. Yang et al. found that SYA exerts an anti-inflammatory effect on BV2 microglia, possibly through the TLR-4/p38/JNK/NF-κB signaling pathway [50]. Besides, it has been reported that HSYA inhibits the phosphorylation of NF-κB and p38 MAPK in BV2 cells in OGD/reoxygeneration (OGD/R) conditions [51]. In addition, HYSA has been reported to activate the HIF-1α/VEGF signaling pathway and then reduce the production of ROS and maintain the integrity of mitochondrial membrane [19]. Raf/MEK/ERK may be another target pathway of SYA, HSYA, and AHSYB to alleviate the inflammatory responses.

FIGURE 5: Effects of SYA, HSYA, and AHSYB on LPS-induced lung NET production in the lungs (MPO: red; histone: green; dsDNA: blue; bar = 100μm).


FIGURE 6: Effects of SYA, HSYA, and AHSYB on NETs. (a) Effects of SYA, HSYA, and AHSYB on plasma MPO-DNA complex in LPS-induced ALI mice. The values presented are mean ± SEM, [#]$P < 0.05$ vs the control group; [**]$P < 0.01$ vs the LPS group. (b) Effects of SYA, HSYA, and AHSYB on MPO-DNA complex in PMA-induced HL-60 cells. [#]$P < 0.05$ vs the control group; [*]$P < 0.05$ vs the PMA group; [**]$P < 0.01$ vs the PMA group.

(a)

(b)

(c)

(d)

FIGURE 7: Effects of SYA, HSYA, and AHSYB on Raf/MEK/ERK signaling pathway expression in the lungs. (a) Protein levels of p-c-Raf, c-Raf, p-MEK, MEK, p-ERK, and ERK in lung homogenates were evaluated by western blot analysis 24 h after LPS injection. (b–d) Densitometric analyses of the relevant bands. The values presented are mean ± SEM. $^{\#\#}P < 0.01$ vs the control group; $^{\#}P < 0.05$ vs the control group; $^{*}P < 0.05$ vs the LPS group; $^{**}P < 0.01$ vs the LPS group.

There are several limitations in our current study. First, we proposed that SYA, HSYA, and AHSYB might protect LPS-induced ALI via NETosis. However, there may be some other potential targets for SYA, HSYA, and AHSYB which are involved in this protective effect. Moreover, NETs can also be generated by a pathway independent of Raf/MEK/ERK [52, 53]. The mechanism underlying the effect of SYA, HSYA, and AHSYB on NET formation may be very complicated, and our data showed that Raf/MEK/ERK might be involved in this effect. Second, the drug dosage used in this study is based on the previous literature [50, 51, 54–56]. We have not investigated the dose-effect of these

three agents. Further pharmacokinetic and toxicological studies may be required to validate the medicinal value of SYA, HSYA, and AHSYB.

5. Conclusion

In summary, this study found that SYA, HSYA, and AHSYB, the three main active components of safflower identified in Xuebijing, can alleviate lung injury induced by LPS and NET formation. Although we do not know the exact mechanism how these constituents act with the inflammatory responses in neutrophils, the inhibition of the Raf/MEK/ERK

(a)

(b)

(c)

(d)

FIGURE 8: Effects of SYA, HSYA, and AHSYB on Raf/MEK/ERK signaling pathway expression in cells. (a) Protein levels of p-c-Raf, c-Raf, p-MEK, MEK, p-ERK, and ERK in cell homogenates were assessed by western blot analysis 3 h after PMA stimulation. (b–d) Densitometric analysis of the relevant bands was performed. The values presented are mean ± SEM. $^{##}P < 0.01$ vs the control group; $^{#}P < 0.05$ vs the control group; $^{*}P < 0.05$ vs the LPS group; $^{**}P < 0.01$ vs the LPS group.

pathway and NET formation might be involved in the mechanism of the protective effect of SYA, HSYA, and AHSYB against LPS-induced lung injury.

Data Availability

The data including HE staining of the lungs, expression of TNF-alpha and IL-6, wet-to-dry weight ratio of lungs, total protein concentration of BALF, number of total cells and neutrophils in BALF, immunofluorescence of NETs in the lungs, level of NETs, and expression of the Raf/MEK/ERK

pathway used to support the findings of this study are included within the article.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors' Contributions

Yun-peng Wang, Yu Guo, and Ping-shan Wen contributed equally to the article. Yun-peng Wang and Yu Guo

performed the research and analyzed the data. Yun-peng Wang and Zhen-zhen Zhao wrote the major part of the manuscript. Jia-feng Wang and Xiao-ming Deng designed the research, ensured correct analysis of the data, and wrote the manuscript. Ping-shan Wen, Jian Xie, Kai Yang, and Qing Yang assisted in the design of the research, oversaw the collection of the data, and contributed to the writing of the manuscript. All authors critically revised the manuscript and gave final approval of the manuscript.

Acknowledgments

References

[1] M. Singer, C. S. Deutschman, C. W. Seymour et al., "The third international consensus definitions for sepsis and septic shock (Sepsis-3)," *JAMA*, vol. 315, no. 8, pp. 801–810, 2016.

[2] B. D. Levy and C. N. Serhan, "Resolution of acute inflammation in the lung," *Annual Review of Physiology*, vol. 76, pp. 467–492, 2014.

[3] S. K. Yoo, T. W. Starnes, Q. Deng, and A. Huttenlocher, "Lyn is a redox sensor that mediates leukocyte wound attraction in vivo," *Nature*, vol. 480, no. 7375, pp. 109–112, 2011.

[4] M. J. Hickey and P. Kubes, "Intravascular immunity: the host-pathogen encounter in blood vessels," *Nature Reviews Immunology*, vol. 9, no. 5, pp. 364–375, 2009.

[5] S. Liu, X. Su, P. Pan et al., "Neutrophil extracellular traps are indirectly triggered by lipopolysaccharide and contribute to acute lung injury," *Scientific Reports*, vol. 6, no. 1, p. 37252, 2016.

[6] V. Brinkmann, "Neutrophil extracellular traps in the second decade," *Journal of Innate Immunity*, vol. 10, no. 5-6, pp. 414–421, 2018.

[7] C. Carmona-Rivera, W. Zhao, S. Yalavarthi, and M. J. Kaplan, "Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2," *Annals of the Rheumatic Diseases*, vol. 74, no. 7, pp. 1417–1424, 2015.

[8] M. Jiménez-Alcázar, C. Rangaswamy, R. Panda et al., "Host DNases prevent vascular occlusion by neutrophil extracellular traps," *Science*, vol. 358, no. 6367, pp. 1202–1206, 2017.

[9] M. Saffarzadeh, C. Juenemann, M. A. Queisser et al., "Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones," *PLoS One*, vol. 7, no. 2, article e32366, 2012.

[10] C. Li, P. Wang, L. Zhang et al., "Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: a meta-analysis of randomized controlled trials," *Journal of Ethnopharmacology*, vol. 224, pp. 512–521, 2018.

[11] Q. Wang, X. Wu, X. Tong, Z. Zhang, B. Xu, and W. Zhou, "Xuebijing ameliorates sepsis-induced lung injury by down-regulating HMGB1 and RAGE expressions in mice," *Evidence-based Complementary and Alternative Medicine*, vol. 2015, Article ID 860259, 9 pages, 2015.

[12] M. W. Liu, Y. H. Wang, C. Y. Qian, and H. Li, "Xuebijing exerts protective effects on lung permeability leakage and lung injury by upregulating Toll-interacting protein expression in rats with sepsis," *International Journal of Molecular Medicine*, vol. 34, no. 6, pp. 1492–1504, 2014.

[13] Y. Song, C. Yao, Y. Yao et al., "XueBiJing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial," *Critical Care Medicine*, vol. 47, no. 9, pp. e735–e743, 2019.

[14] S. H. Xiao, L. Luo, X. H. Liu, Y. M. Zhou, H. M. Liu, and Z. F. Huang, "Curative efficacy and safety of traditional Chinese medicine Xuebijing injections combined with ulinastatin for treating sepsis in the Chinese population: a meta-analysis," *Medicine*, vol. 97, no. 23, article e10971, 2018.

[15] H. Huang, L. Ji, S. Song et al., "Identification of the major constituents in Xuebijing injection by HPLC-ESI-MS," *Phytochemical Analysis*, vol. 22, no. 4, pp. 330–338, 2011.

[16] W. Y. Lai, J. W. Wang, B. T. Huang, E. P. Lin, and P. C. Yang, "A novel TNF-α-targeting aptamer for TNF-α-mediated acute lung injury and acute liver failure," *Theranostics*, vol. 9, no. 6, pp. 1741–1751, 2019.

[17] Y. Zhang, L. Song, R. Pan, J. Gao, B. X. Zang, and M. Jin, "Hydroxysafflor yellow a alleviates lipopolysaccharide-induced acute respiratory distress syndrome in mice," *Biological & Pharmaceutical Bulletin*, vol. 40, no. 2, pp. 135–144, 2017.

[18] A. Manda-Handzlik, W. Bystrzycka, M. Wachowska et al., "The influence of agents differentiating HL-60 cells toward granulocyte-like cells on their ability to release neutrophil extracellular traps," *Immunology and Cell Biology*, vol. 96, no. 4, pp. 413–425, 2018.

[19] X. Song, L. Su, H. Yin, J. Dai, and H. Wei, "Effects of HSYA on the proliferation and apoptosis of MSCs exposed to hypoxic and serum deprivation conditions," *Experimental and Therapeutic Medicine*, vol. 15, no. 6, pp. 5251–5260, 2018.

[20] M. Liu, L. Shi, X. Zou et al., "Caspase inhibitor zVAD-fmk protects against acute pancreatitis-associated lung injury via inhibiting inflammation and apoptosis," *Pancreatology*, vol. 16, no. 5, pp. 733–738, 2016.

[21] W. Shen, J. Gan, S. Xu, G. Jiang, and H. Wu, "Penehyclidine hydrochloride attenuates LPS-induced acute lung injury involvement of NF-kappaB pathway," *Pharmacological Research*, vol. 60, no. 4, pp. 296–302, 2009.

[22] H. Rangé, J. Labreuche, L. Louedec et al., "Periodontal bacteria in human carotid atherothrombosis as a potential trigger for neutrophil activation," *Atherosclerosis*, vol. 236, no. 2, article S0021915014013446, pp. 448–455, 2014.

[23] X. P. Wang, P. F. Wang, J. Q. Bai et al., "Investigating the effects and possible mechanisms of danshen- honghua herb pair on acute myocardial ischemia induced by isoproterenol in rats," *Biomedicine & Pharmacotherapy*, vol. 118, article 109268, 2019.

[24] V. Brinkmann, U. Reichard, C. Goosmann et al., "Neutrophil extracellular traps kill bacteria," *Science*, vol. 303, no. 5663, pp. 1532–1535, 2004.

[25] C. F. Urban, D. Ermert, M. Schmid et al., "Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans," *PLoS Pathogens*, vol. 5, no. 10, article e1000639, 2009.

[26] J. Liu, L. Sun, W. Liu et al., "A nuclease from Streptococcus mutans facilitates biofilm dispersal and escape from killing by neutrophil extracellular traps," *Frontiers in Cellular and Infection Microbiology*, vol. 7, p. 97, 2017.

[27] C. F. Urban and J. E. Nett, "Neutrophil extracellular traps in fungal infection," *Seminars in Cell & Developmental Biology*, vol. 89, pp. 47–57, 2018.

[28] T. Kraaij, S. W. A. Kamerling, L. van Dam et al., "Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA," *Kidney International*, vol. 94, no. 1, pp. 139–149, 2018.

[29] C. H. Lim, S. S. Adav, S. K. Sze, Y. K. Choong, R. Saravanan, and A. Schmidtchen, "Thrombin and plasmin alter the proteome of neutrophil extracellular traps," *Frontiers in Immunology*, vol. 9, p. 1554, 2018.

[30] J. Liu and Z. Dong, "Neutrophil extracellular traps in ischemic AKI: new way to kill," *Kidney International*, vol. 93, no. 2, pp. 303–305, 2018.

[31] A. Warnatsch, M. Ioannou, Q. Wang, and V. Papayannopoulos, "Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis," *Science*, vol. 349, no. 6245, pp. 316–320, 2015.

[32] T. J. Gould, T. T. Vu, L. L. Swystun et al., "Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 34, no. 9, pp. 1977–1984, 2014.

[33] M. Hashiba, A. Huq, A. Tomino et al., "Neutrophil extracellular traps in patients with sepsis," *The Journal of Surgical Research*, vol. 194, no. 1, pp. 248–254, 2015.

[34] J. L. Duan, J. W. Wang, Y. Guan et al., "Safflor yellow A protects neonatal rat cardiomyocytes against anoxia/reoxygenation injury in vitro," *Acta Pharmacologica Sinica*, vol. 34, no. 4, pp. 487–495, 2013.

[35] J. Zou, N. Wang, M. Liu et al., "Nucleolin mediated proangiogenic role of Hydroxysafflor Yellow A in ischaemic cardiac dysfunction: post-transcriptional regulation of VEGF-A and MMP-9," *Journal of Cellular and Molecular Medicine*, vol. 22, no. 5, pp. 2692–2705, 2018.

[36] T. Hu, G. Wei, M. Xi et al., "Synergistic cardioprotective effects of Danshensu and hydroxysafflor yellow A against myocardial ischemia-reperfusion injury are mediated through the Akt/Nrf2/HO-1 pathway," *International Journal of Molecular Medicine*, vol. 38, no. 1, pp. 83–94, 2016.

[37] J. Wang, Q. Zhang, X. Mei, and X. Zhang, "Hydroxysafflor yellow A attenuates left ventricular remodeling after pressure overload-induced cardiac hypertrophy in rats," *Pharmaceutical Biology*, vol. 52, no. 1, pp. 31–35, 2014.

[38] L. Deng, H. Wan, H. Zhou, L. Yu, and Y. He, "Protective effect of hydroxysafflor yellow A alone or in combination with acetylglutamine on cerebral ischemia reperfusion injury in rat: a PET study using ^{18}F-fuorodeoxyglucose," *European Journal of Pharmacology*, vol. 825, pp. 119–132, 2018.

[39] Y. Wang, C. Zhang, W. Peng et al., "Hydroxysafflor yellow A exerts antioxidant effects in a rat model of traumatic brain injury," *Molecular Medicine Reports*, vol. 14, no. 4, pp. 3690–3696, 2016.

[40] Y. He, Q. Liu, Y. Li et al., "Protective effects of hydroxysafflor yellow A (HSYA) on alcohol-induced liver injury in rats," *Journal of Physiology and Biochemistry*, vol. 71, no. 1, pp. 69–78, 2015.

[41] S. Jiang, Z. Shi, C. Li, C. Ma, X. Bai, and C. Wang, "Hydroxysafflor yellow A attenuates ischemia/reperfusion-induced liver injury by suppressing macrophage activation," *International Journal of Clinical and Experimental Pathology*, vol. 7, no. 5, pp. 2595–2608, 2014.

[42] Y. Wang, C. Xue, F. Dong et al., "Hydroxysafflor yellow A attenuates small airway remodeling in a rat model of chronic obstructive pulmonary disease," *Biological & Pharmaceutical Bulletin*, vol. 37, no. 10, pp. 1591–1598, 2014.

[43] Y. L. Liu, Y. J. Liu, Y. Liu et al., "Hydroxysafflor yellow A ameliorates lipopolysaccharide-induced acute lung injury in mice via modulating toll-like receptor 4 signaling pathways," *International Immunopharmacology*, vol. 23, no. 2, pp. 649–657, 2014.

[44] L. Liu, N. Si, Y. Ma et al., "Hydroxysafflor-yellow A induces human gastric carcinoma BGC-823 cell apoptosis by activating peroxisome proliferator-activated receptor gamma (PPARγ)," *Medical Science Monitor*, vol. 24, pp. 803–811, 2018.

[45] J. Zhang, J. Li, H. Song, Y. Xiong, D. Liu, and X. Bai, "Hydroxysafflor yellow A suppresses angiogenesis of hepatocellular carcinoma through inhibition of p38 MAPK phosphorylation," *Biomedicine & Pharmacotherapy*, vol. 109, pp. 806–814, 2019.

[46] J. Liu, S. Yue, Z. Yang et al., "Oral hydroxysafflor yellow A reduces obesity in mice by modulating the gut microbiota and serum metabolism," *Pharmacological Research*, vol. 134, pp. 40–50, 2018.

[47] Y. C. Liu, F. H. Yao, Y. F. Chai, N. Dong, Z. Y. Sheng, and Y. M. Yao, "Xuebijing injection promotes M2 polarization of macrophages and improves survival rate in septic mice," *Evidence-based Complementary and Alternative Medicine*, vol. 2015, Article ID 352642, 9 pages, 2015.

[48] Y. Wang, M. Ji, L. Wang, L. Chen, and J. Li, "Xuebijing injection improves the respiratory function in rabbits with oleic acid-induced acute lung injury by inhibiting IL-6 expression and promoting IL-10 expression at the protein and mRNA levels," *Experimental and Therapeutic Medicine*, vol. 8, no. 5, pp. 1593–1598, 2014.

[49] M. Jiang, M. Zhou, Y. Han et al., "Identification of NF-κB inhibitors in Xuebijing injection for sepsis treatment based on bioactivity-integrated UPLC-Q/TOF," *Journal of Ethnopharmacology*, vol. 147, no. 2, pp. 426–433, 2013.

[50] X. W. Yang, Y. H. Li, H. Zhang et al., "Safflower yellow regulates microglial polarization and inhibits inflammatory response in LPS-stimulated Bv2 cells," *International Journal of Immunopathology and Pharmacology*, vol. 29, no. 1, pp. 54–64, 2016.

[51] J. Li, S. Zhang, M. Lu et al., "Hydroxysafflor yellow A suppresses inflammatory responses of BV2 microglia after oxygen-glucose deprivation," *Neuroscience Letters*, vol. 535, pp. 51–56, 2013.

[52] S. Yousefi, C. Mihalache, E. Kozlowski, I. Schmid, and H. U. Simon, "Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps," *Cell Death and Differentiation*, vol. 16, no. 11, pp. 1438–1444, 2009.

[53] A. Carestia, T. Kaufman, L. Rivadeneyra et al., "Mediators and molecular pathways involved in the regulation of neutrophil extracellular trap formation mediated by activated platelets," *Journal of Leukocyte Biology*, vol. 99, no. 1, pp. 153–162, 2016.

[54] H. Ao, W. Feng, and C. Peng, "Hydroxysafflor yellow A: a promising therapeutic agent for a broad spectrum of diseases," *Evidence-based Complementary and Alternative Medicine*, vol. 2018, Article ID 8259280, 17 pages, 2018.

[55] M. Jin, C. Y. Sun, C. Q. Pei, L. Wang, and P. C. Zhang, "Effect of safflor yellow injection on inhibiting lipopolysaccharide-induced pulmonary inflammatory injury in mice," *Chinese Journal of Integrative Medicine*, vol. 19, no. 11, pp. 836–843, 2013.

[56] Z. Yang, J. Yang, Y. Jia, Y. Tian, and A. Wen, "Pharmacokinetic properties of hydroxysafflor yellow A in healthy Chinese female volunteers," *Journal of Ethnopharmacology*, vol. 124, no. 3, pp. 635–638, 2009.